Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM; AIDS Clinical Trials Group 5170 Study Team. Skiest DJ, et al. Among authors: su z. J Infect Dis. 2007 May 15;195(10):1426-36. doi: 10.1086/512681. Epub 2007 Apr 6. J Infect Dis. 2007. PMID: 17436222 Clinical Trial.
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, Coffin J, Havlir DV. Hare CB, et al. Among authors: su z. Clin Infect Dis. 2008 Aug 1;47(3):421-4. doi: 10.1086/589867. Clin Infect Dis. 2008. PMID: 18558886 Free PMC article. Clinical Trial.
Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
McComsey GA, Walker UA, Budhathoki CB, Su Z, Currier JS, Kosmiski L, Naini LG, Charles S, Medvik K, Aberg JA; AIDS Clinical Trials Group A5229 Team. McComsey GA, et al. Among authors: su z. AIDS. 2010 Oct 23;24(16):2507-15. doi: 10.1097/QAD.0b013e32833ea9bc. AIDS. 2010. PMID: 20827170 Free PMC article. Clinical Trial.
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.
Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM. Wilkin TJ, et al. Among authors: su z. J Acquir Immune Defic Syndr. 2010 Aug;54(5):470-6. doi: 10.1097/qai.0b013e3181e2cba0. J Acquir Immune Defic Syndr. 2010. PMID: 20672447 Free PMC article. Clinical Trial.
Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).
Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team. Crawford KW, et al. Among authors: su z. J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac. J Acquir Immune Defic Syndr. 2010. PMID: 20071999 Free PMC article. Clinical Trial.
7,803 results